Louisiana State Employees Retirement System Sells 200 Shares of Bio-Rad Laboratories Inc. (BIO)
Louisiana State Employees Retirement System decreased its stake in Bio-Rad Laboratories Inc. (NYSE:BIO) by 3.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,600 shares of the company’s stock after selling 200 shares during the period. Louisiana State Employees Retirement System’s holdings in Bio-Rad Laboratories were worth $801,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Bio-Rad Laboratories by 3.3% in the first quarter. Geode Capital Management LLC now owns 130,025 shares of the company’s stock valued at $17,777,000 after buying an additional 4,121 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Bio-Rad Laboratories by 37.1% in the first quarter. Goldman Sachs Group Inc. now owns 110,553 shares of the company’s stock valued at $15,115,000 after buying an additional 29,932 shares in the last quarter. Meeder Asset Management Inc. raised its stake in shares of Bio-Rad Laboratories by 10,254.5% in the first quarter. Meeder Asset Management Inc. now owns 1,139 shares of the company’s stock valued at $156,000 after buying an additional 1,128 shares in the last quarter. State Street Corp raised its stake in shares of Bio-Rad Laboratories by 4.1% in the first quarter. State Street Corp now owns 554,735 shares of the company’s stock valued at $75,838,000 after buying an additional 22,053 shares in the last quarter. Finally, 1832 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories during the first quarter valued at approximately $919,000. Institutional investors own 62.83% of the company’s stock.
Bio-Rad Laboratories Inc. (NYSE:BIO) traded up 1.28% during midday trading on Friday, hitting $163.27. The stock had a trading volume of 271,117 shares. Bio-Rad Laboratories Inc. has a 12-month low of $122.03 and a 12-month high of $164.87. The company’s 50-day moving average price is $157.47 and its 200 day moving average price is $147.16. The stock has a market cap of $4.80 billion, a P/E ratio of 49.52 and a beta of 0.87.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Wednesday, August 3rd. The company reported $0.61 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.52. The business earned $516.80 million during the quarter, compared to analyst estimates of $497.80 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 4.79%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business earned $0.97 EPS. On average, equities research analysts predict that Bio-Rad Laboratories Inc. will post $3.10 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on BIO shares. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Jefferies Group increased their target price on Bio-Rad Laboratories from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, September 7th.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.